Abstract
Introduction. Therapeutic plasma exchange (TPE) removes autoantibodies and immune complexes and plays significant role in the treatment of neurological autoimmune diseases. Current study summarizes 3 year experience of our centre regarding indications and outcomes of TPE in treatment of autoimmune neurological diseases.
Materials and methods. Retrospective analysis of case files of 23 patients with various autoimmune neurological diseases treated with TPE at Department of Renal Diseases and Renal Replacement Therapy of Riga East Clinical University Hospital during 2014-2016 year.
Results. There were 11 males and 12 females. Median age was 58 years (IQR 43-74). TPE was performed due to the current diagnosis: 17 acute polyradiculoneuritis (APRN), 3 myastenia gravis (MG), 2 transverse myelitis (TM) and 1 acute disseminated encephalomyelitis (ADME). Median treatment time was 17 days (interquartile range (IQR) 14-21), 8 were treated in the ICU department with median stay of 16,5 days (IQR 8,75-27,0). As the replacement solution fresh frosen plasma (FFP) only was used in 10 patients, FFP and colloids in 7, FFP and human albumin in 5 and albumin with colloids in 1. Median number of TPE treatments was 4 (IQR 2-5). Median volume of treated plasma 5481 ml (IQR 2094-8587). After the therapy 5 patients had complete response, 11 – partial response, 4 had no response and 3 were dead.
Conclusions. TPE in our centre is mostly used in the treatment of patients with ARPRN, as the replacement solution FFP in combination with colloids or human albumin is the most popular choice. Overall therapy was beneficial for most of the patients (16/23). Current therapeutic approach is in accordance to the international practice.
Materials and methods. Retrospective analysis of case files of 23 patients with various autoimmune neurological diseases treated with TPE at Department of Renal Diseases and Renal Replacement Therapy of Riga East Clinical University Hospital during 2014-2016 year.
Results. There were 11 males and 12 females. Median age was 58 years (IQR 43-74). TPE was performed due to the current diagnosis: 17 acute polyradiculoneuritis (APRN), 3 myastenia gravis (MG), 2 transverse myelitis (TM) and 1 acute disseminated encephalomyelitis (ADME). Median treatment time was 17 days (interquartile range (IQR) 14-21), 8 were treated in the ICU department with median stay of 16,5 days (IQR 8,75-27,0). As the replacement solution fresh frosen plasma (FFP) only was used in 10 patients, FFP and colloids in 7, FFP and human albumin in 5 and albumin with colloids in 1. Median number of TPE treatments was 4 (IQR 2-5). Median volume of treated plasma 5481 ml (IQR 2094-8587). After the therapy 5 patients had complete response, 11 – partial response, 4 had no response and 3 were dead.
Conclusions. TPE in our centre is mostly used in the treatment of patients with ARPRN, as the replacement solution FFP in combination with colloids or human albumin is the most popular choice. Overall therapy was beneficial for most of the patients (16/23). Current therapeutic approach is in accordance to the international practice.
Original language | English |
---|---|
Pages (from-to) | 541 |
Number of pages | 1 |
Journal | Therapeutic Apheresis and Dialysis |
Volume | 21 |
Issue number | 5 |
Publication status | Published - 2017 |
Externally published | Yes |
Event | 11th Congress of the International Society for Apheresis (ISFA) - Tivoli Hotel Congress Centre, Copenhagen, Denmark Duration: 17 May 2017 → 20 May 2017 Conference number: 11 https://www.aconf.org/conf_91227 |
Field of Science*
- 3.1 Basic medicine
- 3.2 Clinical medicine
Publication Type*
- 3.4. Other publications in conference proceedings (including local)